Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTX Biorestorative Therapies	$1.50 +2.0%	$1.62	$1.21 ▼ $2.55	$11.03M	76.7	65,100 shs	26,087 shs
HEB Hemispherx BioPharma	$6.70 -20.0%	$5.94	$1.69 ▼ $14.81	$16.36M	N/A	102,599 shs	7,639 shs
HYPD Hyperion DeFi	$7.04 -2.6%	$8.91	$0.85 ▼ $75.18	$40.51M	2.42	825,566 shs	472,836 shs
PHGE BiomX	$0.48 -35.3%	$0.45	$0.34 ▼ $2.40	$12.44M	1.42	347,190 shs	53,300 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTX Biorestorative Therapies	+4.26%	-1.34%	-9.26%	-14.04%	+2.80%
HEB Hemispherx BioPharma	0.00%	0.00%	0.00%	+6,960.06%	+2,433.08%
HYPD Hyperion DeFi	-7.66%	+33.89%	-45.35%	+512.71%	-89.71%
PHGE BiomX	+7.29%	+33.18%	+36.99%	+6.69%	-68.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRTX Biorestorative Therapies	3.6261 of 5 stars	3.5	5.0	0.0	0.0	2.5	3.3	0.6
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	0.2824 of 5 stars	1.0	0.0	0.0	0.0	2.3	0.8	0.6
PHGE BiomX	1.9904 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRTX Biorestorative Therapies	3.00	Buy	$18.00	1,100.00% Upside
HEB Hemispherx BioPharma	0.00	N/A	N/A	N/A
HYPD Hyperion DeFi	2.00	Hold	$2.00	-71.59% Downside
PHGE BiomX	3.00	Buy	$21.00	4,293.31% Upside

Current Analyst Ratings Breakdown

Latest HEB, HYPD, PHGE, and BRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRTX Biorestorative Therapies	$400K	28.13	N/A	N/A	$1.23 per share	1.22
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	$67.06K	588.18	N/A	N/A	($695.52) per share	-0.01
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRTX Biorestorative Therapies	-$8.98M	-$1.47	N/A	N/A	N/A	-1,772.40%	-122.91%	-81.41%	N/A
HEB Hemispherx BioPharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	N/A
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest HEB, HYPD, PHGE, and BRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	HYPD Hyperion DeFi	N/A	-$2.50	N/A	-$2.50	N/A	N/A
8/12/2025	Q2 2025	BRTX Biorestorative Therapies	-$0.41	-$0.30	+$0.11	-$0.30	$0.34 million	$0.30 million
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million
5/14/2025	Q1 2025	BRTX Biorestorative Therapies	-$0.32	-$0.56	-$0.24	-$0.64	$0.38 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
HEB Hemispherx BioPharma	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRTX Biorestorative Therapies	N/A	2.24	2.24
HEB Hemispherx BioPharma	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	0.34	0.34
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRTX Biorestorative Therapies	69.38%
HEB Hemispherx BioPharma	N/A
HYPD Hyperion DeFi	25.84%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
BRTX Biorestorative Therapies	25.50%
HEB Hemispherx BioPharma	N/A
HYPD Hyperion DeFi	10.86%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRTX Biorestorative Therapies	7	7.50 million	5.59 million	Not Optionable
HEB Hemispherx BioPharma	31	2.44 million	N/A	Not Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable

HEB, HYPD, PHGE, and BRTX Headlines

Recent News About These Companies

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

August 13 at 12:06 PM | seekingalpha.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13 at 6:30 AM | globenewswire.com

What to Expect from BiomX's Earnings

August 12 at 3:46 PM | benzinga.com

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025 | globenewswire.com

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

July 14, 2025 | investing.com

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment

July 14, 2025 | msn.com

PHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron's

July 14, 2025 | barrons.com

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025 | globenewswire.com

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025 | globenewswire.com

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 1, 2025 | globenewswire.com

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

March 31, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEB, HYPD, PHGE, and BRTX Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

$1.50 +0.03 (+2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.33%)

As of 07:53 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Hemispherx BioPharma NYSEAMERICAN:HEB

$6.70 -1.68 (-20.05%)

As of 06/13/2025

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Hyperion DeFi NASDAQ:HYPD

$7.04 -0.19 (-2.63%)

As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

BiomX NYSEMKT:PHGE

$0.48 -0.26 (-35.32%)

Closing price 03:59 PM Eastern

Extended Trading

$0.49 +0.02 (+3.35%)

As of 07:59 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time